scanner-img

IPO Synopsis

Sudeep Pharma Ltd
Registered Office: 129/1/A GIDC Estate Nandesari,,Vadodara-391340, Gujarat
Tel. No: +91 265 284 0656/329 1354
Fax No: NA
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com
Initial public offer of 15,092,749 equity shares of face value of Re.1/- each ("equity shares") of Sudeep Pharma Limited ("company") for cash at a price of Rs.593/- per equity share (including a share premium of Rs.592/- per equity share) ("offer price") aggregating to Rs.895.00 crores comprising a fresh issue of 1,602,023 equity shares of face value of Re.1/- aggregating to Rs. 95.00 crores by the company ("fresh issue") and an offer for sale of 13,490,726 equity shares of face value of Re.1/- aggregating to Rs.800.00 crores ("offered shares") by the selling shareholders, consisting of 3,567,670 equity shares of face value of Re.1/- aggregating to Rs.211.56 crores by SujitJjaysukh Bhayani, 8,418,856 equity shares of face value of Re.1/- aggregating to Rs. 499.24 crores by Sujeet Jaysukh Bhayani HUF, 750,000 equity shares of face value of Re.1/- aggregating to Rs.44.48 crores by Shanil Sujit Bhayani and 754,200 equity shares of face value of Re.1/- aggregating to Rs.44.72 crores by Avani Sujit Bhayani (collectively "the selling shareholders") and such equity shares offered by the selling shareholders ("offer for sale", and together with the fresh issue, the "offer").
Issue Money Payable On
Opens On Closes On Application
21-Nov-2025 25-Nov-2025 ₹593.00 - 0.00
Minimum Application for shares in Nos : 25.0 Further Multiples of :25.0
(₹ Cr) Lead Managers to the Issue
Project Cost 88.48 ICICI Securities Limited
Project Financed through Current Offer 895.00 IIFL Capital Services Limited
Post Issue Equity Share Capital 11.29
Issue Price 593.00
Projects
Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I
General corporate purposes
Promoted By
Sujit Jaysukh Bhayani
Avani Sujit Bhayani
Shanil Sujit Bhayani
Listing At
BSE
NSE
Registrar To The Issue